Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): A randomised, placebo-controlled trial

The Lancet Neurology

Volumn 12, Issue 11, 2013, Pages 1076-1083

  van der Vaart, Thijs ^a   Plasschaert, Ellen ^b,c   Rietman, André B ^a   Renard, Marleen ^b   Oostenbrink, Rianne ^a   Vogels, Annick ^b,c   de Wit, Marie Claire Y ^a   Descheemaeker, Mie Jef ^b   Vergouwe, Yvonne ^a   Catsman Berrevoets, Coriene E ^a   Legius, Eric ^b,c   Elgersma, Ype ^a   Moll, Henriëtte A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; ATTENTION; CHILD; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GASTRITIS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MISSENSE MUTATION; MORNING DOSAGE; MYALGIA; MYOPATHY; NEUROFIBROMA; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SCHOOL CHILD; SCOLIOSIS; SIDE EFFECT; SPATIAL MEMORY; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD BEHAVIOR DISORDERS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEUROFIBROMATOSIS 1; PLACEBOS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885389443     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70227-8     Document Type: Article

References (31)

1. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010, 152A:327-332.
2. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81-88.
3. Hyman SL, Shores A, North KN The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
4. Krab LC, Aarsen FK, de Goede-Bolder A, et al. Impact of neurofibromatosis type 1 on school performance. J Child Neurol 2008, 23:1002-1010.
5. Payne JM, Hyman SL, Shores EA, North KN Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol 2011, 17:313-329.
6. Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008, 300:287-294.
7. Garg S, Lehtonen A, Huson SM, et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol 2013, 55:139-145.
8. Hyman SL, Arthur Shores E, North KN Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 2006, 48:973-977.
9. Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. J Pediatr 2009, 154:420-425.
10. Descheemaeker MJ, Plasschaert E, Frijns JP, Legius E Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group. J Intellect Disabil Res 2013, 57:874-886.
11. Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
12. Cui Y, Costa RM, Murphy GG, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008, 135:549-560.
13. Shilyansky C, Karlsgodt KH, Cummings DM, et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci USA 2010, 107:13141-13146.
14. Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 15:1961-1967.
15. Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011, 45:241-245.
16. Chabernaud C, Mennes M, Kardel PG, et al. Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Neurosci Lett 2012, 515:28-33.
17. Chong PH, Seeger JD, Franklin C Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001, 111:390-400.
18. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011, 23:307-318.
19. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002, 106:2231-2237.
20. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007, 39:1120-1126.
21. Verhulst FC, Van der Ende J, Koot HM Handleiding voor de CBCL/4-18 1996, Academic Medical Center Rotterdam/Erasmus University, Sophia Children's Hospital, Department of Child and Adolescent Psychiatry, Rotterdam.
22. Mautner VF, Kluwe L, Thakker SD, Leark RA Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002, 44:164-170.
23. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010, 376:1658-1669. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group.
24. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997, 54:857-864.
25. Schellenberg EG Music lessons enhance IQ. Psychol Sci 2004, 15:511-514.
26. A randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1 (STARS). (accessed Aug 5, 2013). http://clinicaltrials.gov/show/NCT00853580.
27. van Engelen SJ, Krab LC, Moll HA, et al. Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging. AJNR Am J Neuroradiol 2008, 29:816-822.
28. Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 2010, 25:834-841.
29. Silva AJ, Frankland PW, Marowitz Z, et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 1997, 15:281-284.
30. Ullrich NJ, Ayr L, Leaffer E, Irons MB, Rey-Casserly C Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol 2010, 25:1195-1202.
31. Violante IR, Ribeiro MJ, Edden RA, et al. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain 2013, 136:918-925.